Bristol-Myers Squibb Company (BMY)


NYSE - NYSE Real Time Price. Currency in USD
55.74+0.26 (+0.47%)
At close: 4:01 PM EDT

56.00 0.26 (0.47%)
Pre-Market: 7:40 AM EDT

People also watch:
MRKLLYABTPFEJNJ
Interactive chart
  • 1d
  • 5d
  • 1m
  • 6m
  • YTD
  • 1y
  • 2y
  • 5y
  • 10y
  • Max
1d
Open55.68
Prev Close55.48
Bid55.90 x 1000
Ask56.06 x 400
Day's Range55.50 - 55.89
52wk Range55.02 - 77.12
1y Target EstN/A
Market Cap93.13B
P/E Ratio (ttm)32.60
Beta1.01
Volume8,165,020
Avg Vol (3m)11,209,553
Dividend & Yield1.52 (2.74%)
Earnings DateN/A
Trade prices are not sourced from all markets
  • American City Business Journals16 hours ago

    Big Pharma partners with another Bay Area company in cancer immunotherapy quest

    Bristol-Myers Squibb Co. will test its groundbreaking cancer immunotherapy drug Opdivo with an experimental cancer-fighting drug from Nektar Therapeutics Inc., the companies said Tuesday. The dollar value of the deal wasn't disclosed, but the companies will equally split third-party costs while absorbing their own costs as Opdivo and San Francisco-based Nektar (NKTR) see how the combination therapy works against a broad range of tumors. Opdivo is what's known as a checkpoint inhibitor, which remove the brakes that tumors trick the immune system into applying to help avoid detection.

  • Reutersyesterday

    Bristol-Myers to test Opdivo with Nektar drug for several cancers

    Bristol-Myers Squibb Co said on Tuesday it would evaluate the use of its blockbuster cancer immunotherapy Opdivo in combination with an experimental drug from Nektar Therapeutics to treat multiple cancers. The collaboration involves Nektar's NKTR-214, an experimental immuno-stimulatory therapy designed to increase the expression of PD-1 on immune cells. The trials will evaluate the potential for the combination to improve on the current standard-of-care to treat melanoma and cancers of the kidney, colorectal system, bladder and the most common form of lung cancer.

  • TheStreet.comyesterday

    Bristol, Nektar Research Pact Aims to Boost Efficacy of Cancer Immunotherapy

    A series of clinical trials will test the combination of Bristol-Myers Squibb's Opdivo with Nektar's NKTR-214 in multiple tumor types.